Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo tackles stubborn gut inflammation after colitis surgery

NCT ID NCT06916390

Recruiting now Disease control Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether the drug guselkumab (Tremfya), with or without a low-processed-food diet, can help people with chronic pouchitis—a painful gut condition that can occur after surgery for ulcerative colitis. Twenty adults who have not responded to antibiotics will receive the drug for 48 weeks. The main goal is to see if symptoms improve after 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Guselkumab (Tremfya) and a low-ultra-processed-food, high-fruit diet
What this could lead to
If successful, this could offer a new treatment option for people with chronic pouchitis who don't respond to antibiotics.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The diet part is also exploratory.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POUCHITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pouchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POUCHITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • university hospitals Leuven

    RECRUITING

    Leuven, Vlaams-Brabant, 3000, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.